These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 22562956

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A bioluminescent mouse model of pancreatic {beta}-cell carcinogenesis.
    Zumsteg A, Strittmatter K, Klewe-Nebenius D, Antoniadis H, Christofori G.
    Carcinogenesis; 2010 Aug; 31(8):1465-74. PubMed ID: 20530553
    [Abstract] [Full Text] [Related]

  • 23. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
    Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM, Roskelley CD, Pollak M, Sorensen PH.
    Cancer Res; 2011 Feb 01; 71(3):1060-70. PubMed ID: 21148487
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 26. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
    Bao XH, Takaoka M, Hao HF, Wang ZG, Fukazawa T, Yamatsuji T, Sakurama K, Sun DS, Nagasaka T, Fujiwara T, Naomoto Y.
    Anticancer Res; 2012 Jul 01; 32(7):2827-34. PubMed ID: 22753744
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation.
    Huang CT, Chang MC, Chen YL, Chen TC, Chen CA, Cheng WF.
    Cancer Lett; 2015 Apr 01; 359(1):117-26. PubMed ID: 25592043
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Bielen A, Perryman L, Box GM, Valenti M, de Haven Brandon A, Martins V, Jury A, Popov S, Gowan S, Jeay S, Raynaud FI, Hofmann F, Hargrave D, Eccles SA, Jones C.
    Mol Cancer Ther; 2011 Aug 01; 10(8):1407-18. PubMed ID: 21659463
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells.
    Lamm GM, Christofori G.
    Cancer Res; 1998 Feb 15; 58(4):801-7. PubMed ID: 9485038
    [Abstract] [Full Text] [Related]

  • 33. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R.
    Int J Mol Sci; 2017 Nov 02; 18(11):. PubMed ID: 29099049
    [Abstract] [Full Text] [Related]

  • 34. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, Jänne PA, Saijo N, Minami H.
    Cancer Lett; 2009 Sep 08; 282(1):14-24. PubMed ID: 19345478
    [Abstract] [Full Text] [Related]

  • 35. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
    Hopfner M, Sutter AP, Huether A, Baradari V, Scherubl H.
    World J Gastroenterol; 2006 Sep 21; 12(35):5635-43. PubMed ID: 17007015
    [Abstract] [Full Text] [Related]

  • 36. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.
    Cancer Res; 2003 Dec 15; 63(24):8912-21. PubMed ID: 14695208
    [Abstract] [Full Text] [Related]

  • 37. Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor.
    Jones RA, Campbell CI, Petrik JJ, Moorehead RA.
    Mol Cancer Res; 2008 May 15; 6(5):819-28. PubMed ID: 18505926
    [Abstract] [Full Text] [Related]

  • 38. Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling.
    Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G.
    Oncogene; 2007 Apr 05; 26(16):2290-8. PubMed ID: 17043652
    [Abstract] [Full Text] [Related]

  • 39. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
    Zhang H, Pelzer AM, Kiang DT, Yee D.
    Cancer Res; 2007 Jan 01; 67(1):391-7. PubMed ID: 17210722
    [Abstract] [Full Text] [Related]

  • 40. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
    Whitson BA, Jacobson BA, Frizelle S, Patel MR, Yee D, Maddaus MA, Kratzke RA.
    Ann Thorac Surg; 2006 Sep 01; 82(3):996-1001; discussion 1001-2. PubMed ID: 16928523
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.